Effect of Montelukast on Basophils, In-vitro

Allergic Rhinitis Clinical Trial

Official title:

The Effect of Montelukast In-vitro on Basophil Histamine and Leukotriene, IL-4 Adn IL-13 Release in Subjects With Allergic Rhinitis or Allergic Asthma

Clinical Trial Details — Status: Unknown status

Administrative data

• NCT number: NCT00710450
• Other study ID #: Townley Merck
• Status: Unknown status
• Phase: N/A
• First received: July 1, 2008
• Last updated: September 22, 2011
• Start date: May 2008
• Est. completion date: September 2011

Study information

• Verified date: September 2011
• Source: Creighton University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Subjects with either allergic asthma or allergic rhinitis will be recruited to obtain blood. This blood will be used to be stimulated with to whatever the patient allergic. In the laboratory, this stimulated blood will be measured for histamine, leukotrienes, IL-13 and IL-3. These are chemicals responsible for allergy symptoms.

Recruitment information / eligibility

• Status: Unknown status
• Enrollment: 15
• Est. completion date: September 2011
• Est. primary completion date: September 2011
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years and older

Eligibility

Inclusion Criteria:

• Allergic asthma or allergic rhinitis

• age 12+

Exclusion Criteria:

• smokers

Related Conditions & MeSH terms

• Allergic Asthma
• Allergic Rhinitis
• Asthma
• Rhinitis
• Rhinitis, Allergic

Locations

Country	Name	City	State
United States	Creighton University Medical Center	Omaha	Nebraska

Sponsors (2)

Lead Sponsor	Collaborator
Creighton University	Merck Sharp & Dohme Corp.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Histamine Release		during the assay portion.
Secondary	Cytokine release. IL-13, IL-4 and leukotriene		assay portion